RxDoctor Payments DataLook up a doctor →

Robert Sussman, MD

Pulmonary Disease · Summit, NJNPI 1831190990

Payments from drug & device makers

$644,772in general payments, 2019–2025

Across 718 payments — averaging $898.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$412K
  • Boehringer Ingelheim$70K
  • Genentech USA, Inc.$37K
  • Sanofi US Services Inc.$30K
  • AstraZeneca$26K
  • Roche Products Limited$26K
  • plus $44K from 10 others

What the payments were for

  • Consulting fees$28,7815%
  • Speaking & faculty fees$491,98489%
  • Travel & lodging$17,8523%
  • Food & beverage$12,6662%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$644,772 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$15,880
Medicare patients
86
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter135$153,835
Breo ElliptaFluticasone/Vilanterol123$78,568
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr90$50,838
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$16,563
Arnuity ElliptaFluticasone Furoate30$9,094
Incruse ElliptaUmeclidinium Bromide13$5,295
Qvar RedihalerBeclomethasone Dipropionate12$4,982
Albuterol Sulfate HfaAlbuterol Sulfate71$3,995
Montelukast Sodium17$268
Prednisone24$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$412,305$297,629391 claims
Boehringer IngelheimStiolto Respimat$69,901$16,56318 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$12$4,98212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Summit

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →